Adenomyosis Treatment Market Research Report -Forecast to 2032

Adenomyosis Treatment Market Research Report Information By Type (Focal, Adenomyoma, Diffuse, and Others), By Diagnosis (Endometrial Biopsy, Ultrasound {Transabdominal, and Transvaginal/Endovaginal}, Magnetic Resonance Imaging (MRI), and Others), By Treatment (Anti-Inflammatory Drugs {Ibuprofen, Motrin IB, Advil, and Others}, Hormone Medications {Gonadotropin-Releasing Hormone (GnRH) Agonists, Aromatase Inhibitors, and Others}, Hysterectomy {Supracervial or Subtotal Hysterectomy, Total Hysterectomy, Radical Hysterectomy}, and Others) And By

ID: MRFR/Pharma/2331-HCR | 76 Pages | Author: Kinjoll Dey | February 2024         

Adenomyosis Treatment Market Speak to Analyst Request a Free Sample

Global Adenomyosis Treatment Market Overview


The adenomyosis treatment market size was valued at USD 0.3 Billion in 2022. The adenomyosis treatment industry is projected to grow from USD 0.32 Billion in 2023 to USD 0.52 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.20% during the forecast period (2023 - 2032). The increase in the vulnerable aging population of menopausal women, rise in demand from emerging economies, increase in technological advancements and demand for novel therapies across the globe are the key market drivers enhancing the market growth.
Adenomyosis Treatment Market


Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Adenomyosis Treatment Market Trends



  • The high prevalence of adenomyosis disorders is driving the market growth


Market CAGR for adenomyosis treatment is driven by the increasing women population worldwide; the target population for female reproductive disorders has also increased. Adenomyosis, a gynecologic condition characterized by the existence of endometrial glands in the myometrium, can significantly reduce an individual's lifestyle. Adenomyosis occurs in 8.8% to 61.5% of women undergoing hysterectomy, and rates vary widely by differences in diagnostic criteria and variations between and within pathologists. The prevalence is estimated to range from 20% to 34%, based on patients referred for pelvic imaging rather than the general population of women. Gynecologic disorders affect the female reproductive system. The most common symptoms of gynecologic disorders such as pelvic pain, abnormal vaginal bleeding, endometriosis, adenomyosis, and breast pain and lumps. The importance and severity of these signs often rely on age, as these symptoms may be connected to hormonal changes that happen with aging.


Additionally, the development of imaging techniques, such as MRI and transvaginal ultrasonography (TVUS), has allowed clinicians to make a non-invasive diagnosis of adenomyosis in women undergoing conservative treatments, identifying different disease phenotypes. After some attempts at histological classification, adenomyosis is classified into four subtypes according to MRI lesion localization in the inner or outer myometrium intrinsic, extrinsic, intramural, and indeterminate.


Moreover, a growing number of advancements in medical research to innovate various menopause treatments and products are projected to fuel the market's growth rate. In recent years, several key market participants have conducted research and developmental activities to bring various menopause products and treatments to the market to address the symptoms of menopause. For instance, several non-hormonal drugs have been developed by market participants in recent years that can effectively impact hot flashes and other menopause symptoms. Owing to the growing number of adenomyosis products and services entering the market, the demand for these products is expected to drive the adenomyosis treatment market revenue.


The rising prevalence of vasomotor and menopausal signs, such as night efforts and hot flashes among women during menopausal change, is projected to drive market growth. In addition, problems such as mood swings, problems concentrating, and depression are linked to menopause. As per a study issued in the International Journal of Applied & Basic Medical Research, approximately 36.7% of women registered hot flashes among 87.7% of women conveying menopausal symptoms. The primary symptom noted was anxiety, which accounted for 80%, and sleep problems for 61.2%.


Adenomyosis Treatment Market Segment Insights


Adenomyosis Treatment Type Insights


The adenomyosis treatment market segmentation, based on type, includes focal, adenomyoma, diffuse, and others. The adenomyoma segment dominated the market, accounting for 35% of market revenue (0.11 Billion). In developing economies, category growth is driven as adenomyoma is more commonly observed in women who have had multiple pregnancies or childbirths. However, focal is the fastest-growing category due to the growing elderly population and abnormal hormonal fluctuations.


Adenomyosis Treatment Diagnosis Insights


The adenomyosis treatment market segmentation, based on diagnosis, includes endometrial biopsy, ultrasound {transabdominal and transvaginal/endovaginal}, magnetic resonance imaging (MRI), and others. The magnetic resonance imaging (MRI) category generated the most income (70.4%) due to the increasing geriatric population and technological advancements. However, focal is the fastest-growing category due to rapid technological advancements in healthcare services and the increasing number of individuals admissions to emergency care for focal treatment.


Adenomyosis Treatment Treatment Insights


The adenomyosis treatment market segmentation, based on diagnosis, includes anti-inflammatory drugs {ibuprofen, Motrin IB, Advil, and others}, hormone medications {gonadotropin-releasing hormone (GnRH) agonists, aromatase inhibitors, and others}, hysterectomy {supracervial or subtotal hysterectomy, total hysterectomy, radical hysterectomy}, and others. The anti-inflammatory drugs category generated the most income due to the increasing research and development efforts on developing novel biologics. However, hormone medications are the fastest-growing category as they reduce adenomyotic lesion size and improve the patient's dysmenorrhea and quality of life.


Figure 1 Adenomyosis Treatment Market, by Diagnosis, 2022 & 2032 (USD Billion)
Adenomyosis Treatment Market, by Diagnosis, 2022 & 2032


Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Adenomyosis Treatment Regional Insights


By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American adenomyosis treatment market will dominate, owing to an improved prevalence of post-menstrual syndrome, growing awareness regarding women's fitness, and increased healthcare expenditure will fuel the market growth in this region. Further, the US adenomyosis treatment market held the largest market share, and the Canada adenomyosis treatment market was the fastest growing market in the North American region.


Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 2 ADENOMYOSIS TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)
ADENOMYOSIS TREATMENT MARKET SHARE BY REGION 2022


Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Europe's adenomyosis treatment market accounts for the second-largest market share due to post-menstrual syndrome being prevalent and nutritional needs becoming more widely known in this region. Further, the German adenomyosis treatment market held the largest market share, and the UK adenomyosis treatment market was the fastest-growing market in the European region.


The Asia-Pacific adenomyosis treatment market is projected to grow at the fastest CAGR from 2023 to 2032. This is due to expanding awareness regarding adenomyosis and rising per capita disposable income. Moreover, China’s adenomyosis treatment market held the largest market share, and the Indian adenomyosis treatment market was the fastest-growing market in the Asia-Pacific region.


Adenomyosis Treatment Key Market Players & Competitive Insights


Leading market participants are investing laboriously in research and development to boost their product lines, which will allow the adenomyosis treatment market to grow even better. Market participants are also undertaking various strategic exercises to develop their  footprint, with substantial market developments including the latest product launches, mergers and acquisitions, contractual agreements, higher investments, and collaboration with other organizations. To develop and prevail in a more competitive and growing market climate, the adenomyosis treatment industry must deliver cost-effective items.


Manufacturing locally to decline operating costs is one of the key business tactics manufacturers operate in the adenomyosis treatment industry to help clients and increase the market sector. Major players in the adenomyosis treatment market, including Mayne Pharma Group Limited, Accord Healthcare, Tolmar Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, TerSera Therapeutics LLC, and others, are attempting to expand market need by investing in research and development processes.


Debiopharm is a family-owned biopharmaceutical company founded in 1979 and headquartered in Lausanne, Switzerland. The firm develops biologics and small-molecule drug candidates. Debiopharm drug development covers the formulation, manufacturing, pre-clinical, and clinical stages. Debiopharm products are used for tumors, such as testicular, ovarian, bladder, and lung carcinomas. The company develops biologics and small-molecule drug candidates. Debiopharm drug development covers the formulation, manufacturing, pre-clinical, and clinical stages. Debiopharm products are used for tumors, such as testicular, ovarian, bladder, and lung carcinomas.


Bayer AG is engaged in discovering, developing, manufacturing, and commercializing developments for human health and agriculture. It delivers medicines for women's health, cardiovascular diseases, cancer, hematology, ophthalmology, and other indications. It even aims to develop new molecules and technologies for treatment and modern agriculture. The company's product portfolio includes prescription, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over-the-counter or OTC) products, seeds, crop protection, and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products through wholesalers, pharmacies, hospitals, and retailers. In August 2020, Bayer acquired the UK-based biotech KaNDy Therapeutics Ltd. to develop its drug development pipeline in women's healthcare. KaNDy Therapeutics Ltd. achieved the NT-814 clinical trials to treat menopausal signs such as hot flashes and night sweats.


Key Companies in the Adenomyosis Treatment market include



  • Mayne Pharma Group Limited

  • Accord Healthcare

  • Tolmar Pharmaceuticals, Inc.

  • Boehringer Ingelheim International GmbH

  • TerSera Therapeutics LLC

  • Ferring B.V.

  • Lannett

  • Par Pharmaceutical

  • Hikma Pharmaceuticals PLC

  • Context Therapeutics Inc.

  • Viatris Inc.

  • Bayer AG

  • Teva Pharmaceutical Industries Ltd.

  • AstraZeneca

  • Pfizer Inc.

  • Zydus Pharmaceuticals, Inc.

  • Sun Pharmaceutical Industries Ltd

  • AbbVie Inc.

  • Abbott

  • GlaxoSmithKline plc.


Adenomyosis Treatment Industry Developments


November 2021 Theramex obtained the Femarelle product license to treat menopause symptoms. These products will be available in different markets from the middle of 2022. This drug is used to balance the estrogen levels in women from perimenopause through menopause to post-menopause, relieving the symptoms and conditions.


October 2021 Bayer AG initiated the phase III clinical program OASIS. Under the program, elinzanetant, a dual neurokinin-1, 3 receptor antagonist, will be evaluated on the efficacy and safety standards for treating menopausal symptoms such as vasomotor symptoms.


September 2019 Professor Caroline Gargett and collaborators at the University of Queensland and Monash IVF were awarded a three-year USD 2.07 Million grant to determine the cause of adenomyosis and the physiological processes associated with the disease.


Adenomyosis Treatment Market Segmentation


Adenomyosis Treatment Type Outlook



  • Focal

  • Adenomyoma

  • Diffuse

  • Others


Adenomyosis Treatment Diagnosis Outlook



  • Endometrial Biopsy

  • Ultrasound

    • Transabdominal

    • Transvaginal/Endovaginal



  • Magnetic Resonance Imaging (MRI)

  • Others


Adenomyosis Treatment Outlook



  • Anti-Inflammatory Drugs

    • Ibuprofen

    • Motrin IB

    • Advil

    • Others



  • Hormone Medications

    • Gonadotropin-Releasing Hormone (GnRH) Agonists

    • Aromatase Inhibitors

    • Others



  • Hysterectomy

    • Supracervical Or Subtotal Hysterectomy

    • Total Hysterectomy

    • Radical Hysterectomy



  • Others


Adenomyosis Treatment Regional Outlook



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America



Report Scope:

Adenomyosis Treatment Report Scope
Report Attribute/Metric Details
Market Size 2022 USD 0.3 Billion
Market Size 2023 USD 0.32 Billion
Market Size 2032 USD 0.52 Billion
Compound Annual Growth Rate (CAGR) 6.20% (2023-2032)
Base Year 2022
Market Forecast Period 2023-2032
Historical Data 2018- 2022
Market Forecast Units Value (USD Billion)
Report Coverage Market Competitive Landscape, Revenue Forecast, Growth Factors, and Trends
Segments Covered Type, Treatment, Diagnosis, and Region
Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled Mayne Pharma Group Limited, Accord Healthcare, Tolmar Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, TerSera Therapeutics LLC, Ferring B.V., Lannett, Par Pharmaceutical, Hikma Pharmaceuticals PLC, Context Therapeutics Inc., Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Zydus Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc.
Key Market Opportunities High prevalence of adenomyosis disorders across the globe
Key Market Dynamics Advancement in the diagnosis of adenomyosis
 



Frequently Asked Questions (FAQ) :

The adenomyosis treatment market size was valued at USD 0.3 Billion in 2022.

The market is predicted to expand at a CAGR of 6.20% during the forecast period, 2023-2032.

North America had the most extensive share of the  market

The key players in the market are Hikma Pharmaceuticals PLC, Context Therapeutics Inc., Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Zydus Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc.

The adenomyoma category dominated the adenomyosis treatment market in 2022.

Magnetic resonance imaging (MRI) has the largest share of the market.

The anti-inflammatory drugs had the largest share in the market.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid